As Vice President, New Product Planning and Medical Affairs, Richa Poddar, MBS, plays an integral role in achieving our ambitious goal to be a unique creator of life-changing medicines, by optimizing the competitive positioning of our portfolio of programs as they are developed for the market. Prior to joining Parabilis Medicines, Richa was the Chief Business and Strategy Officer at Matterhorn BioSciences, a discovery stage, cell therapy startup. Before joining Matterhorn, Richa worked as the Chief Commercial Officer at Agios Pharmaceuticals. During her six-year tenure at Agios, she played an instrumental role in launching the company’s first rare disease product, PYRUKYND®, as well as its first two oncology products, TIBSOVO® and IDHIFA®. Richa was in charge of shaping the company’s oncology portfolio by providing strong cross-functional and strategic program leadership. She also spearheaded the transition of the company’s oncology assets to Servier. Richa has held various roles in the pharmaceutical industry, including at Amgen, Clovis Oncology, and Genentech/F. Hoffman La-Roche. In these roles, Richa focused on marketing and market analytics for various oncology products, including Herceptin® and Avastin®. Richa completed her B.E. in computer engineering from Pune University and her master’s in biotechnology (MBS) from Keck Graduate Institute in California.